GSK expands AI drug discovery collaboration with Chai Discovery following successful laboratory evaluation

GSK has expanded its collaboration with Chai Discovery to apply AI-powered protein modelling and molecular design tools across pharmaceutical drug discovery following successful laboratory validation.

The agreement gives GSK access to Chai Discovery's AI models for protein folding and molecular design, following laboratory evaluations that identified binders across all tested targets using designs generated without target-specific training.

The collaboration strengthens GSK's AI-enabled discovery capabilities and demonstrates growing pharmaceutical interest in computational approaches that can generate experimentally validated molecular candidates.

Field	Content
Article Type	Deals
Companies	GSK; Chai Discovery
Deal Type	AI drug discovery collaboration
Technology/Modality	Artificial intelligence-based protein modelling and molecular design
Platform Capabilities	Protein folding prediction and molecular binder design
Collaboration Scope	Application of Chai Discovery's AI models to drug discovery activities within GSK's research pipeline
Validation Results	Laboratory testing identified binders across all evaluated targets using designs generated without target-specific training
Financial Terms	Not disclosed
Development Stage	Discovery and preclinical research
Therapy Areas	Not specified in the supplied announcement summary
Geography	International pharmaceutical research collaboration
What Happened	GSK entered a collaboration with Chai Discovery following successful laboratory evaluation of its AI-powered protein modelling and molecular design technology.
Why It Matters	The partnership provides further pharmaceutical validation of AI-generated molecular designs and could improve the efficiency of early-stage drug discovery.
Supporting Context	GSK's laboratory evaluation identified binders across all tested targets without target-specific model training.
Strategic Rationale	GSK gains access to specialised AI molecular design capabilities while Chai Discovery expands the pharmaceutical application of its technology.
Potential Impact	The collaboration could accelerate identification and optimisation of molecular candidates across selected drug discovery programmes.
Key Takeaway	GSK and Chai Discovery have established a substantive AI drug discovery collaboration supported by successful experimental validation.
What to Watch	Expansion into additional discovery programmes, disclosure of therapeutic targets, experimental validation results and advancement of AI-designed candidates.
Primary Source	Chai Discovery
Relevant Date	9 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com